Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of cancer metabolism on therapy resistance – Clinical implications
Ana Cristina Gonçalves, Elena Richiardone, Joana Jorge, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100797-100797
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Hao-Ran Jin, Jin Wang, Zijing Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 114
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 94
Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy
Lei Cao, Huixiang Tian, Man Fang, et al.
Biomaterials (2022) Vol. 290, pp. 121856-121856
Open Access | Times Cited: 92
Emerging therapies in cancer metabolism
Yi Xiao, Tian‐Jian Yu, Ying Xu, et al.
Cell Metabolism (2023) Vol. 35, Iss. 8, pp. 1283-1303
Open Access | Times Cited: 90
Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein
Chenmala Karthika, R. Sureshkumar, Mehrukh Zehravi, et al.
Life (2022) Vol. 12, Iss. 6, pp. 897-897
Open Access | Times Cited: 76
Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer
Ziyou Lin, Jingwei Li, Jian Zhang, et al.
Cancer Research (2023) Vol. 83, Iss. 13, pp. 2187-2207
Open Access | Times Cited: 45
Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy
Xinyue Shao, Xiaoling Zhao, Binghao Wang, et al.
Theranostics (2025) Vol. 15, Iss. 5, pp. 1689-1714
Open Access | Times Cited: 2
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells
Cristina P. R. Xavier, Dimas Carolina Belisario, Rita Rebelo, et al.
Drug Resistance Updates (2022) Vol. 62, pp. 100833-100833
Open Access | Times Cited: 57
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma
Manfei Pi, Huixian Kuang, Chunyan Yue, et al.
Drug Resistance Updates (2022) Vol. 61, pp. 100822-100822
Closed Access | Times Cited: 56
The Effect of Oxidative Phosphorylation on Cancer Drug Resistance
Ziyi Zhao, Yong Mei, Ziyang Wang, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 62-62
Open Access | Times Cited: 53
The dual role of autophagy in acute myeloid leukemia
Wonhyoung Seo, Prashanta Silwal, Ik‐Chan Song, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 39
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications
Philippe Icard, Luca Simula, Ludovic Fournel, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100852-100852
Open Access | Times Cited: 39
Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S. Fleishman, Sihang Cheng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?
Ravichandran Vishwa, Bandari BharathwajChetty, Sosmitha Girisa, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 293-319
Open Access | Times Cited: 11
Custom‐Design of Multi‐Stimuli‐Responsive Degradable Silica Nanoparticles for Advanced Cancer‐Specific Chemotherapy
Junjie Zhang, Jiani Zhou, Longguang Tang, et al.
Small (2024) Vol. 20, Iss. 35
Closed Access | Times Cited: 10
Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming
Ting Yu, Zhaoyun Liu, Qingxu Tao, et al.
Cancer Letters (2024) Vol. 589, pp. 216824-216824
Open Access | Times Cited: 9
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Therapeutic targeting of glutamate dehydrogenase 1 that links metabolic reprogramming and Snail-mediated epithelial–mesenchymal transition in drug-resistant lung cancer
Qizhi Wang, Ming Wu, Haobin Li, et al.
Pharmacological Research (2022) Vol. 185, pp. 106490-106490
Open Access | Times Cited: 27
Correlation between the Warburg effect and progression of triple-negative breast cancer
Shaojun Liu, Yuxuan Li, Meng Yuan, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 19
Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer
Lijie Zhou, Kaixuan Du, Yiheng Dai, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma
Valentin Van den Bossche, Julie Vignau, Engy Vigneron, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Targeting TRAP1-Dependent Metabolic Reprogramming to Overcome Doxorubicin Resistance in Quiescent Breast Cancer
Muhammad Zubair Saleem, Ruyi Huang, Yingying Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101226-101226
Open Access
Thyroid hormones inhibit tumor progression and enhance the antitumor activity of lenvatinib in hepatocellular carcinoma via reprogramming glucose metabolism
Chun‐Cheng Yang, Yu‐Chuan Yan, Guo‐Qiang Pan, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer
Bingfeng Lu, Shuo Chen, Xue Guan, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells
Chenmala Karthika, R. Sureshkumar, Mehrukh Zehravi, et al.
Life (2022) Vol. 12, Iss. 6, pp. 811-811
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top